8.30 Registration and welcome coffee

9.00 Opening remarks from the chair
Dr Fintan Walton, Chief Executive, PharmaVentures (UK)

ANTI-CANCER THERAPIES

PRODUCT COMMERCIALISATION

9.40 Fast-tracking your product pipeline
Dr Alan Robertson, CEO, Pharmaxis

10.40 Morning tea

EQUITY FINANCE

11.10 Attracting investment partners
Dr Ian Nisbet, CEO, Xenome

BOOSTING AUSTRALIA’S BIOTECHNOLOGY CAPABILITIES

11.40 [Keynote address] Nurturing the biotechnology industry
• Reportcard from NSW
• Key funding areas
• Supporting innovation
• Future support and funding priorities
The Hon Ian Macdonald, Minister for State Development (NSW)

12.10 [Case study] Advances in encapsulation and controlled-released technology
• Latest developments
• Applications for the biotechnology and life sciences sector
• Commercial partnerships
• Market applications
• Technology platforms
Dr Christophe Barbe, Chief Technical Officer, CeramiSphere (ANSTO)

12.40 [Case study] Driving top-line growth through new products, while managing the bottom line
• Innovating in a competitive market
• Building strategic alliances and partnerships
• Nurturing the industry’s capabilities
• Delivering on innovative R&D strategies
Dr Daniel Grant, Head of Strategic Alliances Worldwide (Business Development), Pfizer Australia

1.00 Luncheon

*XENO CELL THERAPIES *CANCER THERAPEUTICS *FOSSIL FUELS
*CONTROLLED RELEASE TECHNOLOGY *RESPIRATORY DISORDERS

AWARD-WINNING VACCINES

3.00 Afternoon tea

3.30 [Case study] Biomass to cellulosic ethanol
• Collaboration with Syngenta (Syngenta Centre for Sugarcane Biofuels Development)
• Using genetic technology to produce cheaper ethanol from sugarcane
• Commercial potential of gene activation technology
Professor James Dale, Chief Scientific Officer, Farmacule Bioindustries & Member,
Queensland Biotechnology Advisory Council

4.00 [Case study] Preventing and treating common diseases, including respiratory disorders
• Tracking early stage developments
• Tapping into markets with unmet needs
• Identifying merger and acquisition opportunities
Professor Robert Clancy, AM, Director and Chairman, Hunter Immunology Limited

4.30 Closing remarks from the chair & cocktail function

Click here to register

8.30 Welcome coffee

9.00 Opening remarks from the chair
Professor Silviu Itescu, Founder and Chief Scientific Advisor, Mesoblast Limited

MERGERS AND ACQUISITIONS

BUSINESS DEVELOPMENT AND CAPITAL RAISINGS

9.40 [Case study] Rebirthing a biotech venture in the Australian environment
• The re-birthing of Athlomics
• Australian attitudes to ‘failure’
• Lessons learned for business development & capital raising
Dr Roslyn Brandon, CEO, Athlomics

CANCER THERAPIES

10.40 Preparing for successful deal making
• Opportunities for Australian companies
• Outlook for:
-strategic alliances
-licensing
-joint ventures
-mergers and acquisitions
-equity financing
Dr Fintan Walton, Chief Executive, PharmaVentures (UK)

STEM CELL THERAPIES

11.10 [Case study] Fast-tracking stem cell therapies
Professor Silviu Itescu, Founder and Chief Scientific Advisor, Mesoblast Limited

11.40 Rejuvenating immune systems using stem cell therapies
• Manipulation of the immune system to enable successful stem cell therapies
• Establishment of banking of multiple stem cell types, focusing on the newborn
• Treatment applications for human and veterinary markets
Dr Richard Boyd, Director, Monash Immunology and Stem Cell Laboratory

BOARDROOM CHALLENGES

12.10 [Panel discussion] Staying competitive in a dynamic industry
• How do you maximise the value of your assets?
• Why is the competitive landscape changing?
• Which models will work to drive new growth?
-Mergers and acquisitions
-Co-development
-Outsourcing
-Out-licensing
-Spin-outs
Colin Mackie, Head of Corporate Development, Clinuvel Pharmaceuticals
Alison Coutts, Director, Martin Place Securities
Stephen Pattillo, Director, Australia & New Zealand, Indiana Economic Development Corporation

1.00 Lunch

2.00 [Panel discussion] Expanding into US markets
• Markets developments
• Opportunities and challenges
• What it takes to be a winner
• Sustainable strategies for growth
Chair: Stephen Pattillo, Director, Australia & New Zealand, Indiana Economic Development Corporation
Donal O’Dwyer, Chairman, Atcor Medical
Ben Dillon, CEO & Managing Director, Polartechnics
Colin Sutton, Director, Mission

2.30 Tracking new venture capital and private equity
• 21st century venture capital opportunities
• Drug discovery stocks/technologies with a winning streak
• Domestic performance vs global markets
• Current strengths and capabilities
Matt McNamara, General Manager, Intersuisse Bioscience Managers

3.00 Afternoon tea

INVESTMENT OUTLOOK

3.30 Building competitive advantage for Australian biotechs
• What factors constrain the development of Australian biotech companies relative to their US equivalents?
• In what areas is Australia relatively advantaged?
• Which business strategies are succeeding for Australian biotechs?
Dr Merilyn Sleigh, Director, InAvanti, Life Sciences Consulting

4.00 Open for business: facilitating VC investment in Australian public biotechnology companies
• Investment strategies
• Supporting companies at their IPO
• Partnering with public companies
Dr Steve Gourley, Venture Partner, GBS Venture Partners

4.30 Closing remarks from the chair

4.40 Close of summit

Click here to register